Page last updated: 2024-08-26

sr141716 and Depression

sr141716 has been researched along with Depression in 33 studies

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's24 (72.73)29.6817
2010's9 (27.27)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stavreva, GT; Tashev, RE; Velikova, MS1
Butler, P; Munafò, MR; Nutt, DJ; Robinson, ES; Stuart, SA1
Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Longo, BM; Marinho, EA; Oliveira-Lima, AJ; Patti, CL; Santos, R; Takatsu-Coleman, AL; Wuo-Silva, R; Yokoyama, TS1
Antoniou, K; Delis, F; Gueye, AB; Laviolette, SR; Le Foll, B; Loureiro, M; Makriyannis, A; Poulia, N; Pryslawsky, Y; Trigo, JM; Vemuri, K1
Joca, SRL; Kirkedal, C; Liebenberg, N; Moreira, F; Wegener, G1
Kapoor, S1
Chaput, JP; Tremblay, A1
Soyka, M1
Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U1
Faludi, G; Halmy, L; Purebl, G; Rihmer, Z1
Gorzalka, BB; Hill, MN1
Kim, DH; Lee, S; Ryu, JH; Yoon, SH1
Browning, M; Cowen, PJ; Di Simplicio, M; Harmer, CJ; Horder, J1
Assareh, N; ElBatsh, MM; Kendall, DA; Marsden, CA1
Boggs, DL; Buchanan, RW; Conley, RR; Gold, JM; Gorelick, DA; Huestis, MA; Kelly, DL; Linthicum, J; Liu, F; McMahon, RP; Waltz, J1
Elbatsh, MM; Kendall, DA; Marsden, CA; Moklas, MA1
Borrelli, F; Capasso, F; Capasso, R; Izzo, AA; Mascolo, N1
Griebel, G; Scatton, B; Stemmelin, J1
Gadde, KM1
Roberfroid, D1
Cahill, K; Ussher, M2
Holsboer, F; Lutz, B; Marsicano, G; Nestler, EJ; Steiner, MA; Wotjak, CT1
Mitchell, PB; Morris, MJ1
Astrup, A; Bartels, EM; Bliddal, H; Christensen, R; Kristensen, PK1
Boekholdt, SM; Jukema, JW; Peters, RJ1
Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H1
Nau, JY1
Al-Zaman, Y; Aylwin, S1
Forslund, T; Hjemdahl, P; Raaschou, P; Wettermark, B1
Després, JP; Pi-Sunyer, X; Scheen, A; Van Gaal, L1
Blüher, M1
Di Marzo, V; Szallasi, A1

Reviews

7 review(s) available for sr141716 and Depression

ArticleYear
Rimonabant and depression.
    Pharmacopsychiatry, 2008, Volume: 41, Issue:5

    Topics: Alcoholism; Animals; Depression; Humans; Piperidines; Pyrazoles; Rimonabant

2008
[Association of obesity and depression].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2008, Volume: 10, Issue:4

    Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disorder; Circadian Rhythm; Cyclobutanes; Depression; Depressive Disorder, Major; Dietary Carbohydrates; Energy Intake; Ghrelin; Humans; Hypothalamo-Hypophyseal System; Insulin Resistance; Leptin; Obesity; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rimonabant; Seasonal Affective Disorder; Sleep Wake Disorders; Surveys and Questionnaires; Weight Gain; Weight Loss

2008
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
    The Cochrane database of systematic reviews, 2007, Jul-18, Issue:3

    Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking Cessation; Smoking Prevention; Suicide

2007
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
    The Cochrane database of systematic reviews, 2007, Oct-17, Issue:4

    Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Suicide

2007
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
    Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600

    Topics: Anti-Obesity Agents; Anxiety Disorders; Depression; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss

2007
[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47

    Topics: Cardiovascular Diseases; Depression; Diet, Reducing; Humans; Lipids; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss

2007
Emerging concepts in the medical and surgical treatment of obesity.
    Frontiers of hormone research, 2008, Volume: 36

    Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide

2008

Trials

3 trial(s) available for sr141716 and Depression

ArticleYear
Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.
    Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:1

    Topics: Adult; Anxiety Disorders; Depression; Emotions; Female; Humans; Male; Memory, Short-Term; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Recognition, Psychology; Rimonabant; Young Adult

2012
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.
    Schizophrenia research, 2012, Volume: 134, Issue:2-3

    Topics: Adolescent; Adult; Analysis of Variance; Cannabinoid Receptor Antagonists; Cognition Disorders; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Piperidines; Psychiatric Status Rating Scales; Pyrazoles; Rimonabant; Schizophrenia; Treatment Outcome; Young Adult

2012
Depression and anxiety with rimonabant.
    Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600

    Topics: Anti-Obesity Agents; Anxiety; Depression; Humans; Meta-Analysis as Topic; Piperidines; Pyrazoles; Rimonabant

2007

Other Studies

23 other study(ies) available for sr141716 and Depression

ArticleYear
Subchronic Central Administration of Cannabinoid Ligands Modulates Nociception in Bulbectomized Rats.
    Folia medica, 2019, 12-31, Volume: 61, Issue:4

    Topics: Animals; Depression; Disease Models, Animal; Dronabinol; Ligands; Male; Nociception; Olfactory Bulb; Pain Threshold; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant

2019
A translational rodent assay of affective biases in depression and antidepressant therapy.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:9

    Topics: Affect; Animals; Antidepressive Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Carbolines; Depression; Discrimination Learning; Disease Models, Animal; Environment; Isotretinoin; Male; Piperidines; Pyrazoles; Rats; Reward; Rimonabant; Stress, Psychological; Translational Research, Biomedical

2013
Effects of rimonabant on the development of single dose-induced behavioral sensitization to ethanol, morphine and cocaine in mice.
    Progress in neuro-psychopharmacology & biological psychiatry, 2015, Apr-03, Volume: 58

    Topics: Akathisia, Drug-Induced; Animals; Animals, Outbred Strains; Anxiety; Cannabinoid Receptor Antagonists; Central Nervous System Depressants; Cocaine; Depression; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Ethanol; Male; Mice; Morphine; Motor Activity; Narcotics; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders

2015
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
    The international journal of neuropsychopharmacology, 2016, Volume: 19, Issue:12

    Topics: Animals; Anxiety; Behavior, Addictive; Behavior, Animal; Cannabinoid Receptor Antagonists; Cues; Depression; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Inverse Agonism; Drug-Seeking Behavior; Male; Maze Learning; Mesencephalon; Motivation; Motor Activity; Piperidines; Pyrazoles; Rats, Long-Evans; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Swimming; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Weight Loss

2016
A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats.
    Acta neuropsychiatrica, 2017, Volume: 29, Issue:6

    Topics: Amidohydrolases; Animals; Antidepressive Agents; Arachidonic Acids; Behavior, Animal; Cannabinoid Receptor Antagonists; Depression; Dose-Response Relationship, Drug; Drug Inverse Agonism; Male; Piperidines; Prefrontal Cortex; Pyrazoles; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin; TRPV Cation Channels

2017
Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome.
    Clinical endocrinology, 2009, Volume: 70, Issue:2

    Topics: Cannabinoid Receptor Antagonists; Depression; Female; Humans; Metabolic Diseases; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant

2009
Depression and weight loss: opposite outcome for surgery and rimonabant?
    Obesity reviews : an official journal of the International Association for the Study of Obesity, 2008, Volume: 9, Issue:5

    Topics: Anti-Obesity Agents; Depression; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Safety; Treatment Outcome; Weight Loss

2008
The endocannabinoid system as a target for obesity treatment.
    Clinical cornerstone, 2008, Volume: 9, Issue:1

    Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabinoids; Humans; Lactones; Life Style; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Pyridines; Rimonabant; Risk

2008
Impairments in endocannabinoid signaling and depressive illness.
    JAMA, 2009, Mar-18, Volume: 301, Issue:11

    Topics: Affect; Anti-Obesity Agents; Antidepressive Agents; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Depression; Depressive Disorder; Endocannabinoids; Humans; Ligands; Obesity; Piperidines; Pyrazoles; Research; Rimonabant; Signal Transduction; Tobacco Use Disorder

2009
Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus.
    Neuroscience letters, 2009, Dec-25, Volume: 467, Issue:2

    Topics: Animals; Anti-Obesity Agents; Behavior, Animal; Bromodeoxyuridine; Cell Count; Depression; Doublecortin Domain Proteins; Doublecortin Protein; Hippocampus; Immunohistochemistry; Male; Mice; Mice, Inbred ICR; Microtubule-Associated Proteins; Neurogenesis; Neurons; Neuropeptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stress, Psychological

2009
The effects of chronic administration of tranylcypromine and rimonabant on behaviour and protein expression in brain regions of the rat.
    Pharmacology, biochemistry, and behavior, 2012, Volume: 100, Issue:3

    Topics: Animals; Antidepressive Agents; Avoidance Learning; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Depression; Drug Inverse Agonism; Frontal Lobe; Male; Monoamine Oxidase Inhibitors; Motor Activity; Nerve Tissue Proteins; Phosphorylation; Piperidines; Protein Processing, Post-Translational; Pyrazoles; Random Allocation; Rats; Rats, Inbred Strains; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Tranylcypromine

2012
Antidepressant-like effects of Δ⁹-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression.
    Pharmacology, biochemistry, and behavior, 2012, Volume: 102, Issue:2

    Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Depression; Disease Models, Animal; Dronabinol; Frontal Lobe; Hippocampus; Male; MAP Kinase Signaling System; Olfactory Bulb; Piperidines; Pyrazoles; Rats; Rimonabant

2012
Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
    Urology, 2004, Volume: 64, Issue:1

    Topics: Acetylcholine; Adenosine Triphosphate; Animals; Anthracenes; Antidepressive Agents; Atropine; Bridged Bicyclo Compounds; Capsaicin; Depression; Electric Stimulation; Female; Haloperidol; Hypericum; Kaempferols; Male; Methysergide; Muscle Contraction; Muscle, Smooth; Naloxone; Perylene; Phentolamine; Phloroglucinol; Piperidines; Plant Extracts; Propranolol; Pyrazoles; Quercetin; Rats; Rats, Wistar; Rimonabant; Rutin; Terpenes; Tetrodotoxin; Urinary Bladder; Urinary Incontinence; Verapamil

2004
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.
    Biological psychiatry, 2005, Feb-01, Volume: 57, Issue:3

    Topics: Aggression; Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Diazepam; Dose-Response Relationship, Drug; Electroshock; Emotions; Fluoxetine; Gerbillinae; Immobility Response, Tonic; Male; Maze Learning; Mice; Models, Animal; Neuropsychological Tests; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant

2005
Effect of rimonabant on weight and cardiometabolic risk factors.
    JAMA, 2006, Aug-09, Volume: 296, Issue:6

    Topics: Anti-Obesity Agents; Anxiety; Depression; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors

2006
Rimonabant in obese patients with type 2 diabetes.
    Lancet (London, England), 2007, Feb-17, Volume: 369, Issue:9561

    Topics: Depression; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss

2007
Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice.
    Psychoneuroendocrinology, 2008, Volume: 33, Issue:1

    Topics: Adaptation, Psychological; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Corticosterone; Depression; Desipramine; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Statistics, Nonparametric; Stress, Psychological; Swimming; Time Factors

2008
[New drugs; rimonabant].
    Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47

    Topics: Appetite Regulation; Cardiovascular Diseases; Depression; Diet, Reducing; Energy Intake; Humans; Lipids; Lipogenesis; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss

2007
[Antiobesity drugs--new limitations].
    Revue medicale suisse, 2007, Nov-28, Volume: 3, Issue:135

    Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Depression; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lactones; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Suicide; Weight Loss

2007
[Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].
    Lakartidningen, 2007, Dec-19, Volume: 104, Issue:51-52

    Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Depression; Drug Approval; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss

2007
Efficacy and safety of the weight-loss drug rimonabant.
    Lancet (London, England), 2008, Feb-16, Volume: 371, Issue:9612

    Topics: Anti-Obesity Agents; Depression; Depressive Disorder, Major; Humans; Obesity; Patient Selection; Piperidines; Pyrazoles; Rimonabant; Suicide

2008
Efficacy and safety of the weight-loss drug rimonabant.
    Lancet (London, England), 2008, Feb-16, Volume: 371, Issue:9612

    Topics: Anti-Obesity Agents; Depression; Depressive Disorder, Major; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant

2008
Rimonabant in rats with a metabolic syndrome: good news after the depression.
    British journal of pharmacology, 2008, Volume: 154, Issue:5

    Topics: Animals; Anti-Inflammatory Agents; Body Weight; Depression; Disease Models, Animal; Inflammation Mediators; Leukocytes; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant

2008